Quantitative Imaging Biomarkers

QIBs: The Basics - Numbers Game Unlocked

• QIB: Objective, quantifiable image-derived metric; measures (patho)physiology.
• Purpose: Disease detection, staging, prognosis, monitoring treatment response.
• Hallmarks (📌 RARP): Repeatability, Accuracy, Reproducibility, Precision.
• Key Examples:
  • ADC (DWI): Low values (e.g., < 1.0 x $10^{-3} \text{ mm}^2/\text{s}$) suggest restricted diffusion (tumors, ischemia).
  • SUV (PET): High values (e.g., SUVmax > 2.5) often indicate malignancy.
  • RECIST: Standardized tumor response criteria.
• Workflow:

⭐ QIBs like ADC and SUV are crucial for differentiating benign vs. malignant lesions and assessing early treatment response.

PET QIBs - Sweet Spots & Hot Counts

• Standardized Uptake Value (SUV): Primary PET QIB.
  • $SUV_{max}$: Max uptake in Region of Interest (ROI).
  • $SUV_{mean}$: Avg. uptake in ROI.
  • $SUV_{peak}$: Avg. in small ROI around $SUV_{max}$; robust.
  • Influencers: Blood glucose, uptake time, patient size, reconstruction.
• Metabolic Tumor Volume (MTV): Volume of tumor with uptake > threshold.
• Total Lesion Glycolysis (TLG): $MTV \times SUV_{mean}$; total metabolic burden.
• PERCIST 1.0: Standardizes solid tumor PET response.
  • Uses $SUL_{peak}$ (SUV normalized to liver). Tracks up to 5 lesions.

  ⭐ $SUV_{peak}$ is preferred in PERCIST: less noise-sensitive, more reproducible than $SUV_{max}$.

• Deauville Score (Lymphoma): 5-point FDG-PET response.
  • Compares lesion to mediastinum (M) & liver (L).
  • 1: No uptake. 2: Uptake ≤M. 3: Uptake >M but ≤L. 4: Mod. >L. 5: Marked >L/new.
  • Scores 1-3 often indicate good response/Complete Metabolic Response (CMR).

MRI QIBs - Mapping Micro‑Worlds

• MRI QIBs: Objective, numerical data on tissue properties.
• Key Techniques:
  • DWI/ADC: Measures water diffusion. ADC ($mm^2/s$) ↓ in tumors, ischemia; ↑ in cysts.

    ⭐ ADC values are critical for differentiating malignant from benign lesions and assessing early ischemic stroke.

  • DTI/FA: White matter integrity. FA (0-1) reflects diffusion directionality. For TBI, MS.
  • DCE-MRI: Perfusion & permeability ($K^{trans}$, $v_e$, $k_{ep}$). Tumor angiogenesis.
  • MRS: Metabolite levels (NAA, Cho, Cr, Lac). 📌 "Chopping Tumors": Cho ↑ (tumors). NAA ↓ (neuronal injury).
  • ASL: Non-contrast perfusion (CBF in $mL/100g/min$).
  • Relaxometry (T1, T2, T2 maps):* Quantitative relaxation times. T1: myocardial fibrosis; T2: cartilage; T2*: iron.

QIBs: Validation & Clinics - Trust The Numbers

QIBs provide objective measures, but rigorous validation is crucial for clinical confidence and "trusting the numbers."

• Validation Pathway:
  • Technical: Confirms QIB measurement integrity (Accuracy, Precision, Repeatability, Reproducibility).
  • Biological/Clinical: Establishes QIB relevance to disease status or treatment efficacy.
• Clinical Significance:
  • Enhances diagnostic accuracy, staging, and prognostic assessment.
  • Objectively monitors therapy response (e.g., RECIST, ADC [malignancy often < 1.0 x $10^{-3}$ mm²/s], SUV).
  • QIBA (Quantitative Imaging Biomarkers Alliance) spearheads standardization efforts.

⭐ ADC values (DWI) are pivotal QIBs; ↓ADC often indicates malignancy due to restricted diffusion in dense cellular areas.

• Adoption Challenges: Achieving widespread standardization, managing inter-scanner/operator variability, seamless clinical workflow integration.

High‑Yield Points - ⚡ Biggest Takeaways

• QIBs: Objective, measurable features from images, enabling quantitative medical assessment.
• Vital for diagnosis, staging, prognosis, and tracking treatment response accurately.
• Common examples: ADC (DWI), SUV (PET), HU (CT), T1/T2 maps (MRI).
• Allow non-invasive monitoring of disease activity and therapeutic effects.
• Reproducibility and standardization are crucial for reliable clinical application.
• Challenges: Technical variability, ensuring robust validation across diverse settings.
• Key drivers for precision medicine, radiomics, and AI in healthcare.